ITGAV and prostate cancer: MiR-197 has been shown to regulate the expression of ITGAV via the STAT5 pathway, thereby affecting the proliferation, invasion, and metastasis of prostate cancer cells, while miR-197 can also inhibit the growth of prostate cancer by targeting ITGAV and regulating the development of PCSCs through the STAT5 pathway (Ju et al., 2021).